Why the study?
Does GASP-2 promote proliferation and differentiation in C2C12 myoblasts?
Does GASP-2 promote proliferation and differentiation in C2C12 myoblasts?
GASP-2 promotes myoblast proliferation and differentiation by inhibiting the canonical myostatin pathway, independent of its glycosylation status.
GASP-2 glycosylation may modulate myogenesis in vitro; leaves open therapeutic relevance pending in vivo validation.
GASP-2 is a secreted multi-domain glycoprotein known as a specific inhibitor of myostatin and GDF-11. Here we investigate the role of GASP-2 on myogenesis and the effect of its glycosylation on its activity. GASP-2 overexpression or knockdown by shRNAs were carried out on C2C12 myoblasts cells. In silico analysis of GASP-2 protein was performed to identify its glycosylation sites. We produced a mouse recombinant GASP-2 protein in a prokaryotic system to obtain a fully deglycosylated protein allowing us to study the importance of this post-translational modification on GASP-2 activity. Both mature and deglycosylated GASP-2 proteins increase C2C12 proliferation and differentiation by inhibiting the myostatin pathway. In silico and western-blot analyses revealed that GASP-2 presents one consensus sequence for N-glycosylation and six potential sites of mucin-type O-glycosylation. GASP-2 promotes myogenesis and thus independently of its glycosylation. This is the first report demonstrating that GASP-2 promotes proliferation and differentiation of myoblasts by inhibiting the canonical pathway of myostatin.
No takes yet. Share an insight, caveat, or question.
Pèrié et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: